{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:15:14Z","timestamp":1768637714318,"version":"3.49.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020617","name":"Minnesota State University, Mankato","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020617","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00277-025-06298-x","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:40:49Z","timestamp":1741653649000},"page":"2403-2416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MYC networks associate with decreased CD8 T-cell presence in diffuse large B-cell lymphoma and may be addressed by the synergistic combination of AZD4573 and Selinexor \u2013 a preliminary analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Alison C.","family":"Rutz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kennedee S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidan L.","family":"Forberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Nik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Unrau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainslee J.","family":"Hemmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Minicozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5367-6640","authenticated-orcid":false,"given":"Keenan T.","family":"Hartert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"6298_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73. https:\/\/doi.org\/10.3322\/caac.21763","DOI":"10.3322\/caac.21763"},{"key":"6298_CR2","doi-asserted-by":"publisher","unstructured":"Sehn LH, Salles G (2021) Diffuse large B-Cell lymphoma. 384:842\u2013858. https:\/\/doi.org\/10.1056\/NEJMra2027612. Diffuse","DOI":"10.1056\/NEJMra2027612"},{"key":"6298_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced Non-Hodgkin\u2019s lymphoma. N Engl J Med 328:1002\u20131006. https:\/\/doi.org\/10.1056\/NEJM199304083281404","journal-title":"N Engl J Med"},{"key":"6298_CR4","doi-asserted-by":"publisher","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP et al (2022) Polatuzumab Vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med 386. https:\/\/doi.org\/10.1056\/nejmoa2115304","DOI":"10.1056\/nejmoa2115304"},{"key":"6298_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130:1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"key":"6298_CR6","doi-asserted-by":"publisher","unstructured":"Ekstroem Smedby KE, Ekberg S, Eloranta S, Enblad G, Jerkeman M, Andersson P-O et al Treatment intensity, timing of relapse and outcome of 713 relapsed\/Refractory diffuse large B-Cell lymphoma (DLBCL) in a Population-Based setting in Sweden. Blood 2019;134. https:\/\/doi.org\/10.1182\/blood-2019-123785","DOI":"10.1182\/blood-2019-123785"},{"key":"6298_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5866","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP, Witzig TE, Haioun C, Thompson CA et al (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2013.51.5866","journal-title":"J Clin Oncol"},{"key":"6298_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science (80-). https:\/\/doi.org\/10.1126\/science.aar6711","journal-title":"Science"},{"key":"6298_CR9","doi-asserted-by":"publisher","unstructured":"Buecklein V, Blumenberg V, Ackermann J, Schmidt C, Rejeski K, Mueller N et al Single-Center experience with Axicabtagene-Ciloleucel (Axi-cel) and tisagenlecleucel (Tisa-cel) for relapsed\/refractory diffuse large B-Cell lymphoma: comparable response rates and manageable toxicity. Blood 2020;136. https:\/\/doi.org\/10.1182\/blood-2020-142932","DOI":"10.1182\/blood-2020-142932"},{"key":"6298_CR10","doi-asserted-by":"publisher","unstructured":"Sermer D, Batlevi C, Lia Palomba M, Shah G, Lin RJ, Perales MA et al (2020) Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv 4. https:\/\/doi.org\/10.1182\/bloodadvances.2020002118","DOI":"10.1182\/bloodadvances.2020002118"},{"key":"6298_CR11","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis L, Miklos D, Jacobson CA et al Kte-C19 (anti-CD19 CAR T Cells) induces complete remissions in patients with refractory diffuse large B-Cell lymphoma (DLBCL): results from the pivotal phase 2 Zuma-1. Blood 2016;128:LBA-6 LP-LBA-6.","DOI":"10.1182\/blood.V128.22.LBA-6.LBA-6"},{"key":"6298_CR12","doi-asserted-by":"publisher","unstructured":"Brudno JN, Kochenderfer JN (2018) Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol 15. https:\/\/doi.org\/10.1038\/nrclinonc.2017.128","DOI":"10.1038\/nrclinonc.2017.128"},{"key":"6298_CR13","doi-asserted-by":"publisher","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO et al Five-year follow-up of ZUMA-1 supports the curative potential of Axicabtagene Ciloleucel in refractory large B-cell lymphoma. Blood 2023;141. https:\/\/doi.org\/10.1182\/blood.2022018893","DOI":"10.1182\/blood.2022018893"},{"key":"6298_CR14","doi-asserted-by":"publisher","unstructured":"Chong EA, Ruella M, Schuster SJ (2021) Five-Year outcomes for refractory B-Cell lymphomas with CAR T-Cell therapy. N Engl J Med 384. https:\/\/doi.org\/10.1056\/nejmc2030164","DOI":"10.1056\/nejmc2030164"},{"key":"6298_CR15","doi-asserted-by":"publisher","unstructured":"Faramand R, Kotani H, Morrissey D, Yu B, Locke FL, Jain M et al (2019) Prediction of CAR T-Related toxicities in R\/R DLBCL patients treated with Axicabtagene Ciloleucel using point of care cytokine measurements. Biol Blood Marrow Transpl 25. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.827","DOI":"10.1016\/j.bbmt.2018.12.827"},{"key":"6298_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"aa Alizadeh","year":"2000","unstructured":"Alizadeh aa, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald a et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503\u2013511. https:\/\/doi.org\/10.1038\/35000501","journal-title":"Nature"},{"key":"6298_CR17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536433","author":"DW Scott","year":"2014","unstructured":"Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES et al (2014) Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. https:\/\/doi.org\/10.1182\/blood-2013-11-536433","journal-title":"Blood"},{"key":"6298_CR18","doi-asserted-by":"publisher","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A et al Genetic and functional drivers of diffuse large B cell lymphoma. Cell 2017. https:\/\/doi.org\/10.1016\/j.cell.2017.09.027","DOI":"10.1016\/j.cell.2017.09.027"},{"key":"6298_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0016-8","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. https:\/\/doi.org\/10.1038\/s41591-018-0016-8","journal-title":"Nat Med"},{"key":"6298_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ et al (2018) Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1801445","journal-title":"N Engl J Med"},{"key":"6298_CR21","doi-asserted-by":"publisher","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E et al (2020) Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. https:\/\/doi.org\/10.1182\/blood.2019003535","DOI":"10.1182\/blood.2019003535"},{"key":"6298_CR22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood-2019-127399","volume":"134","author":"C Rushton","year":"2019","unstructured":"Rushton C, Arthur SE, Alcaide M, Cheung M, Thomas N, Hilton LK et al (2019) Recurrent patterns of clonal evolution in Relapsed-Refractory DLBCL following treatment with R-CHOP. Blood 134:921\u2013921. https:\/\/doi.org\/10.1182\/blood-2019-127399","journal-title":"Blood"},{"key":"6298_CR23","doi-asserted-by":"publisher","unstructured":"Rushton CK, Arthur SE, Alcaide M, Cheung M, Jiang A, Coyle KM et al (2020) Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv 4. https:\/\/doi.org\/10.1182\/bloodadvances.2020001696","DOI":"10.1182\/bloodadvances.2020001696"},{"key":"6298_CR24","doi-asserted-by":"publisher","unstructured":"Rushton C, Alcaide M, Cheung M, Michaud NR, Daigle S, Rys RN et al The copy number landscape of relapsed and refractory diffuse large B-Cell lymphoma. Blood 2020;136. https:\/\/doi.org\/10.1182\/blood-2020-142871","DOI":"10.1182\/blood-2020-142871"},{"key":"6298_CR25","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","volume":"22","author":"RD Morin","year":"2016","unstructured":"Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L et al (2016) Genetic landscapes of relapsed and refractory diffuse large B-Cell lymphomas. Clin Cancer Res 22:2290\u20132300. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2123","journal-title":"Clin Cancer Res"},{"key":"6298_CR26","doi-asserted-by":"publisher","unstructured":"Hilton LK, Ngu HS, Collinge B, Dreval K, Ben-Neriah S, Rushton CK et al Relapse timing is associated with distinct evolutionary dynamics and response to salvage therapy in DLBCL. Blood 2022;140. https:\/\/doi.org\/10.1182\/blood-2022-160187","DOI":"10.1182\/blood-2022-160187"},{"key":"6298_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02143","author":"R Shouval","year":"2021","unstructured":"Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S et al (2021) Impact of TP53 genomic alterations in large B-Cell lymphoma treated with CD19-Chimeric antigen receptor T-Cell therapy. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.21.02143","journal-title":"J Clin Oncol"},{"key":"6298_CR28","doi-asserted-by":"publisher","unstructured":"Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M et al (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell 42. https:\/\/doi.org\/10.1016\/j.ccell.2024.02.011","DOI":"10.1016\/j.ccell.2024.02.011"},{"key":"6298_CR29","doi-asserted-by":"publisher","unstructured":"Jaeger U, Bishop MR, Salles G, Schuster SJ, Maziarz RT, Han X et al Myc expression and Tumor-Infiltrating T cells are associated with response in patients (Pts) with relapsed\/refractory diffuse large B-Cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel in the Juliet trial. Blood 2020;136. https:\/\/doi.org\/10.1182\/blood-2020-137045","DOI":"10.1182\/blood-2020-137045"},{"key":"6298_CR30","doi-asserted-by":"publisher","unstructured":"Jain MD, Ziccheddu B, Coughlin CA, Faramand R, Griswold AJ, Reid KM et al Genomic drivers of large B-Cell lymphoma resistance to CD19 CAR-T therapy. Blood 2021;138. https:\/\/doi.org\/10.1182\/blood-2021-148605","DOI":"10.1182\/blood-2021-148605"},{"key":"6298_CR31","doi-asserted-by":"publisher","unstructured":"Hill BT, Roth CJ, Kositsky R, Dave T, Love C, McKinney M et al Impact of molecular features of diffuse large B-Cell lymphoma on treatment outcomes with Anti-CD19 chimeric antigen receptor (CAR) T-Cell therapy. Blood 2021;138. https:\/\/doi.org\/10.1182\/blood-2021-145764","DOI":"10.1182\/blood-2021-145764"},{"key":"6298_CR32","doi-asserted-by":"publisher","unstructured":"Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A et al Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell 2023;41. https:\/\/doi.org\/10.1016\/j.ccell.2022.12.005","DOI":"10.1016\/j.ccell.2022.12.005"},{"key":"6298_CR33","doi-asserted-by":"publisher","unstructured":"Wang Y, Tong C, Lu Y, Wu Z, Guo Y, Liu Y et al (2023) Characteristics of premanufacture CD8\u2009+\u2009T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. Signal Transduct Target Ther 8. https:\/\/doi.org\/10.1038\/s41392-023-01659-2","DOI":"10.1038\/s41392-023-01659-2"},{"key":"6298_CR34","doi-asserted-by":"publisher","unstructured":"Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B et al (2020) Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26. https:\/\/doi.org\/10.1038\/s41591-020-1061-7","DOI":"10.1038\/s41591-020-1061-7"},{"key":"6298_CR35","doi-asserted-by":"publisher","unstructured":"Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z et al Clinical and biological subtypes of b-cell lymphoma revealed by microenvironmental signatures. Cancer Discov 2021;11. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0839","DOI":"10.1158\/2159-8290.CD-20-0839"},{"key":"6298_CR36","doi-asserted-by":"publisher","unstructured":"Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY et al The landscape of tumor cell States and ecosystems in diffuse large B cell lymphoma. Cancer Cell 2021;39. https:\/\/doi.org\/10.1016\/j.ccell.2021.08.011","DOI":"10.1016\/j.ccell.2021.08.011"},{"key":"6298_CR37","doi-asserted-by":"publisher","unstructured":"Ye X, Wang L, Nie M, Wang Y, Dong S, Ren W et al (2022) A single-cell atlas of diffuse large B cell lymphoma. Cell Rep 39. https:\/\/doi.org\/10.1016\/j.celrep.2022.110713","DOI":"10.1016\/j.celrep.2022.110713"},{"key":"6298_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02754-1","author":"FL Locke","year":"2024","unstructured":"Locke FL, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P et al (2024) Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat Med. https:\/\/doi.org\/10.1038\/s41591-023-02754-1","journal-title":"Nat Med"},{"key":"6298_CR39","doi-asserted-by":"publisher","unstructured":"Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C et al (2022) Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med 28. https:\/\/doi.org\/10.1038\/s41591-022-01916-x","DOI":"10.1038\/s41591-022-01916-x"},{"key":"6298_CR40","doi-asserted-by":"publisher","unstructured":"Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N et al (2022) Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med 28. https:\/\/doi.org\/10.1038\/s41591-022-01959-0","DOI":"10.1038\/s41591-022-01959-0"},{"key":"6298_CR41","doi-asserted-by":"publisher","unstructured":"Kurtz DM, Soo J, Alig S, Keh LCT, Macaulay C, Jin MC et al Phased variant enrichment for enhanced minimal residual disease detection from Cell-Free DNA. Blood 2019;134. https:\/\/doi.org\/10.1182\/blood-2019-131267","DOI":"10.1182\/blood-2019-131267"},{"key":"6298_CR42","doi-asserted-by":"publisher","unstructured":"Good Z, Spiegel JY, Sahaf B, Malipatlolla MB, Ehlinger ZJ, Kurra S et al Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nat Med 2022;28. https:\/\/doi.org\/10.1038\/s41591-022-01960-7","DOI":"10.1038\/s41591-022-01960-7"},{"key":"6298_CR43","doi-asserted-by":"publisher","unstructured":"Yan Z, Li L, Fu D, Wu W, Qiao N, Huang Y et al (2023) Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. Front Med 17. https:\/\/doi.org\/10.1007\/s11684-022-0972-8","DOI":"10.1007\/s11684-022-0972-8"},{"key":"6298_CR44","doi-asserted-by":"publisher","unstructured":"Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR et al Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov 2022;3. https:\/\/doi.org\/10.1158\/2643-3230.BCD-22-0018","DOI":"10.1158\/2643-3230.BCD-22-0018"},{"key":"6298_CR45","doi-asserted-by":"publisher","unstructured":"Yan X, Chen D, Ma X, Wang Y, Guo Y, Wei J et al (2022) CD58 loss in tumor cells confers functional impairment of CAR T cells. Blood Adv 6. https:\/\/doi.org\/10.1182\/bloodadvances.2022007891","DOI":"10.1182\/bloodadvances.2022007891"},{"key":"6298_CR46","doi-asserted-by":"publisher","unstructured":"Majzner RG, Frank MJ, Mount C, Tousley A, Kurtz DM, Sworder B et al CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with Axicabtagene Ciloleucel but can be overcome through novel CAR engineering. Blood 2020;136. https:\/\/doi.org\/10.1182\/blood-2020-139605","DOI":"10.1182\/blood-2020-139605"},{"key":"6298_CR47","doi-asserted-by":"publisher","unstructured":"Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K et al (2017) Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov 7. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0538","DOI":"10.1158\/2159-8290.CD-17-0538"},{"key":"6298_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL (2023) CAR immune cells: design principles, resistance and the next generation. Nature. 614https:\/\/doi.org\/10.1038\/s41586-023-05707-3","journal-title":"Nature"},{"key":"6298_CR49","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A et al (2014) An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123:837\u2013842. https:\/\/doi.org\/10.1182\/blood-2013-09-524108","journal-title":"Blood"},{"key":"6298_CR50","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009309","author":"G Shouse","year":"2023","unstructured":"Shouse G, Kaempf A, Gordon MJ, Artz AS, Yashar D, Sigmund AM et al (2023) A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2022009309","journal-title":"Blood Adv"},{"key":"6298_CR51","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","volume":"117","author":"SM Aukema","year":"2011","unstructured":"Aukema SM, Siebert R, Schuuring E, Van Imhoff GW, Kluin-Nelemans HC, Boerma EJ et al (2011) Double-hit B-cell lymphomas. Blood 117:2319\u20132331. https:\/\/doi.org\/10.1182\/blood-2010-09-297879","journal-title":"Blood"},{"key":"6298_CR52","doi-asserted-by":"publisher","unstructured":"Vaidya R, Witzig TE Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol 2014. https:\/\/doi.org\/10.1093\/annonc\/mdu109","DOI":"10.1093\/annonc\/mdu109"},{"key":"6298_CR53","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1182\/blood.V92.9.3152","volume":"92","author":"MH Kramer","year":"1998","unstructured":"Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH et al (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152\u20133162","journal-title":"Blood"},{"key":"6298_CR54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","volume":"151","author":"Z Nie","year":"2012","unstructured":"Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W et al (2012) c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151:68\u201379. https:\/\/doi.org\/10.1016\/j.cell.2012.08.033","journal-title":"Cell"},{"key":"6298_CR55","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/ni.2418","volume":"13","author":"DP Calado","year":"2012","unstructured":"Calado DP, Sasaki Y, Godinho SA, Pellerin A, K\u00f6chert K, Sleckman BP et al (2012) The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol 13:1092\u20131100. https:\/\/doi.org\/10.1038\/ni.2418","journal-title":"Nat Immunol"},{"key":"6298_CR56","doi-asserted-by":"publisher","unstructured":"Xu-Monette ZY, Deng Q, Manyam GC, Tzankov A, Li L, Xia Y et al (2016) Clinical and biologic significance of MYC genetic mutations in de Novo diffuse large B-cell lymphoma. Clin Cancer Res 22. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2296","DOI":"10.1158\/1078-0432.CCR-15-2296"},{"key":"6298_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ddtec.2016.06.004","volume":"19","author":"G Andrieu","year":"2016","unstructured":"Andrieu G, Belkina AC, Denis GV (2016) Clinical trials for BET inhibitors run ahead of the science. Drug Discov Today Technol 19:45\u201350. https:\/\/doi.org\/10.1016\/j.ddtec.2016.06.004","journal-title":"Drug Discov Today Technol"},{"key":"6298_CR58","doi-asserted-by":"publisher","unstructured":"Chapuy B, Stewart C, Wood T, Dunford A, Wienand K, Getz G et al Validation of the Genetically-Defined DLBCL subtypes and generation of a parsimonious probabilistic classifier. Blood 2019;134. https:\/\/doi.org\/10.1182\/blood-2019-131250","DOI":"10.1182\/blood-2019-131250"},{"key":"6298_CR59","doi-asserted-by":"publisher","unstructured":"Xu-Monette ZY, Wei L, Fang X, Au Q, Nunns H, Nagy M et al (2022) Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC\/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma. Clin Cancer Res 28. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2949","DOI":"10.1158\/1078-0432.CCR-21-2949"},{"key":"6298_CR60","doi-asserted-by":"publisher","unstructured":"Vera de Jonge A, Mutis T, Roemer MGM, Scheijen B, Chamuleau MED (2020) Impact of Myc on anti-tumor immune responses in aggressive B cell non-hodgkin lymphomas: consequences for cancer immunotherapy. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12103052","DOI":"10.3390\/cancers12103052"},{"key":"6298_CR61","doi-asserted-by":"publisher","unstructured":"Kuruvilla J, Savona M, Baz R, Mau-Sorensen PM, Gabrail N, Garzon R et al Selective Inhibition of nuclear export with Selinexor in patients with non-Hodgkin lymphoma. Blood 2017;129. https:\/\/doi.org\/10.1182\/blood-2016-11-750174","DOI":"10.1182\/blood-2016-11-750174"},{"key":"6298_CR62","unstructured":"Luo B, Huang L, Gu Y, Li C, Lu H, Chen G et al (2018) Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses. Int J Clin Exp Pathol; 11"},{"key":"6298_CR63","doi-asserted-by":"publisher","unstructured":"Azizian NG, Azizian NG, Li Y, Li Y (2020) XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncol 13. https:\/\/doi.org\/10.1186\/s13045-020-00903-4","DOI":"10.1186\/s13045-020-00903-4"},{"key":"6298_CR64","doi-asserted-by":"publisher","unstructured":"Thieme E, Bruss N, Sun D, Dominguez EC, Coleman D, Liu T et al CDK9 Inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma. Mol Cancer 2023;22. https:\/\/doi.org\/10.1186\/s12943-023-01762-6","DOI":"10.1186\/s12943-023-01762-6"},{"key":"6298_CR65","doi-asserted-by":"publisher","unstructured":"Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, Martin MS et al (2020) AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res 26. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1853","DOI":"10.1158\/1078-0432.CCR-19-1853"},{"key":"6298_CR66","doi-asserted-by":"publisher","unstructured":"Sworder B, Kurtz DM, Macaulay C, Frank MJ, Alig S, Garofalo A et al Circulating DNA for molecular response prediction, characterization of resistance mechanisms and quantification of CAR T-Cells during Axicabtagene Ciloleucel therapy. Blood 2019;134. https:\/\/doi.org\/10.1182\/blood-2019-129015","DOI":"10.1182\/blood-2019-129015"},{"key":"6298_CR67","doi-asserted-by":"publisher","unstructured":"Xu-Monette ZY, Zhang H, Zhu F, Tzankov A, Bhagat G, Visco C et al (2020) A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv 4. https:\/\/doi.org\/10.1182\/bloodadvances.2020001949","DOI":"10.1182\/bloodadvances.2020001949"},{"key":"6298_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05478-x","author":"AL Forberg","year":"2023","unstructured":"Forberg AL, Unrau J, Weber KS, Rutz AC, Lund S, Guidinger J et al (2023) Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-023-05478-x","journal-title":"Ann Hematol"},{"key":"6298_CR69","doi-asserted-by":"publisher","unstructured":"Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J et al Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood 2020;135. https:\/\/doi.org\/10.1182\/blood.2019002121","DOI":"10.1182\/blood.2019002121"},{"key":"6298_CR70","doi-asserted-by":"publisher","unstructured":"Roider T, Seufert J, Uvarovskii A, Frauhammer F, Bordas M, Abedpour N et al (2020) Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. Nat Cell Biol 22. https:\/\/doi.org\/10.1038\/s41556-020-0532-x","DOI":"10.1038\/s41556-020-0532-x"},{"key":"6298_CR71","doi-asserted-by":"publisher","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsd\u00f3ttir H, Tamayo P, Mesirov JP Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011;27. https:\/\/doi.org\/10.1093\/bioinformatics\/btr260","DOI":"10.1093\/bioinformatics\/btr260"},{"key":"6298_CR72","doi-asserted-by":"publisher","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102. https:\/\/doi.org\/10.1073\/pnas.0506580102","DOI":"10.1073\/pnas.0506580102"},{"key":"6298_CR73","doi-asserted-by":"publisher","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF et al (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462. https:\/\/doi.org\/10.1038\/nature08460","DOI":"10.1038\/nature08460"},{"key":"6298_CR74","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ng0506-500","volume":"38","author":"M Reich","year":"2006","unstructured":"Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP (2006) GenePattern 2.0 [2]. Nat Genet 38:500\u2013501. https:\/\/doi.org\/10.1038\/ng0506-500","journal-title":"Nat Genet"},{"key":"6298_CR75","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btl196","author":"J Gould","year":"2006","unstructured":"Gould J, Getz G, Monti S, Reich M, Mesirov JP (2006) Comparative gene marker selection suite. Bioinformatics. https:\/\/doi.org\/10.1093\/bioinformatics\/btl196","journal-title":"Bioinformatics"},{"key":"6298_CR76","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp427","author":"J Chen","year":"2009","unstructured":"Chen J, Bardes EE, Aronow BJ, Jegga AG (2009) ToppGene suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkp427","journal-title":"Nucleic Acids Res"},{"key":"6298_CR77","doi-asserted-by":"publisher","unstructured":"Vallania F, Tam A, Lofgren S, Schaffert S, Azad TD, Bongen E et al (2018) Leveraging heterogeneity across multiple datasets increases cell-mixture Deconvolution accuracy and reduces biological and technical biases. Nat Commun 9. https:\/\/doi.org\/10.1038\/s41467-018-07242-6","DOI":"10.1038\/s41467-018-07242-6"},{"key":"6298_CR78","doi-asserted-by":"publisher","DOI":"10.1534\/g3.113.007674","author":"Z Ouyang","year":"2013","unstructured":"Ouyang Z, Hardee J, Kundaje A, Zhang Y, Snyder M, Lacroute P (2013) STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-Cell lymphoma. G3: Genes|Genomes|Genetics. https:\/\/doi.org\/10.1534\/g3.113.007674","journal-title":"G3: Genes|Genomes|Genetics"},{"key":"6298_CR79","doi-asserted-by":"publisher","unstructured":"Ianevski A, Giri AK, Aittokallio T (2021) SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res 48. https:\/\/doi.org\/10.1093\/NAR\/GKAA216","DOI":"10.1093\/NAR\/GKAA216"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06298-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06298-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06298-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:13:58Z","timestamp":1746414838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06298-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6298"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06298-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study. All de-identified patient and genomics datasets were assembled from previously-published and publicly-available analyses.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No potential conflicts of interest relevant to this article were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s disclosures of potential conflicts of interest"}},{"value":"Each author has contributed to this manuscript substantially and intellectually and shares the public responsibility for its contents. Each author warrants that his\/her contributions to this manuscript are original works not published wholly or partly elsewhere, except in the form of an abstract; that he\/she will not submit it to other journals except in the case of editorial rejection and in the case of duplicate publication that was approved by both editors-in-chief of the first and second journals; and that the manuscript contains nothing unlawful, invading the right of privacy, or infringing a proprietary right, so that the journal should not be responsible for such legal affairs. Each author warrants the transfer of the copyright, interest, authorship, and all rights regarding this manuscript to the publisher, in case of publication. The copyright agreement has been agreed upon by all parties at the time of May 2023.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Copyright transfer agreement"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}